Current Assets
Cash & Equivalents
Bristol-Myers Squibb Cash & Equivalents decreased by 6.2% to $9.57B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.0%, from $10.88B to $9.57B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -7.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ4 2012
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase suggests strong liquidity and potential for investment, while a decrease may indicate heavy capital expenditure or debt repayment.
Detailed definition
This represents the most liquid assets held by the company, including currency, demand deposits, and short-term investme...
Peer comparison
Pharmaceutical peers typically maintain significant cash balances to fund R&D and strategic acquisitions.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.4B | $13.88B | $14.32B | $12.58B | $10.96B | $7.96B | $9.33B | $9.05B | $8.43B | $7.57B | $11.46B | $9.33B | $6.29B | $7.89B | $10.35B | $10.88B | $12.6B | $15.73B | $10.21B | $9.57B |
| QoQ Change | — | +21.8% | +3.1% | -12.1% | -12.9% | -27.4% | +17.2% | -3.0% | -6.9% | -10.2% | +51.5% | -18.6% | -32.6% | +25.4% | +31.1% | +5.1% | +15.9% | +24.8% | -35.1% | -6.2% |
| YoY Change | — | — | — | — | -3.8% | -42.7% | -34.9% | -28.1% | -23.1% | -4.9% | +22.9% | +3.1% | -25.3% | +4.3% | -9.8% | +16.6% | +100.2% | +99.3% | -1.3% | -12.0% |
Range$6.29B – $15.73B
CAGR-3.6%
Avg YoY Growth+3.8%
Median YoY Growth-4.4%
Current Streak2 quarters decline
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's cash & equivalents?
- Bristol-Myers Squibb (BMY) reported cash & equivalents of $9.57B in Q1 2026.
- How has Bristol-Myers Squibb's cash & equivalents changed year-over-year?
- Bristol-Myers Squibb's cash & equivalents decreased by 12.0% year-over-year, from $10.88B to $9.57B.
- What is the long-term trend for Bristol-Myers Squibb's cash & equivalents?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's cash & equivalents has grown at a -7.4% compound annual growth rate (CAGR), from $14.97B to $10.21B.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets immediately available to the company.